

ASX: MEM 20 May 2024

INVESTOR WEBINAR INVITATION

Australian-based reproductive biotechnology company, Memphasys Limited (ASX: MEM), is pleased to announce as part of an ongoing national and international roadshow, the Company is inviting shareholders and prospective investors to a webinar presentation.

The webinar will be held via Zoom at:

1pm AEST / 11am AWST Wednesday 22nd May 2024

Registration is available through the following link:

https://us02web.zoom.us/webinar/register/WN SyPavCgcR2iAoldeQL683w

The investor webinar will be delivered by Acting Managing Director / CEO Dr David Ali and will also include participation from Non-Executive Chairman Robert Cooke, as well as Memphasys Scientific Director Dr John Aitken.

The format of the webinar will include a formal presentation providing an in-depth overview of the Company's diverse and innovative project pipeline¹, and will also feature interactive Q&A.

Webinar attendees will have the opportunity to submit questions directly to management during the Q&A session, and are also encouraged to submit questions in advance via email to the following address: dtasker@chapteroneadvisors.com.au.

A recorded copy of the webinar will be made available following the event.

This announcement has been approved for release by the board of Memphasys Limited.

ENDS

For further information, please contact:

Dr David Ali

Acting Managing Director / Chief Executive Officer Memphasys Limited

Tel: +61 2 8415 7300

E: david.ali@memphasys.com

David Tasker

Managing Director Chapter One Advisors Tel: +61 433 112 936

E: dtasker@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company's patented bio-separation technology, utilised by the Company's most advanced product, the Felix™ System device, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.

¹ Refer to ASX Announcement dated: 9 May 2024